A small molecule that was discovered using a binding site prediction approach and in vitro fragment screening can disrupt the MIA–FN interaction by binding to a specific pocket on the MIA protein; it can serve as a potential target during future drug development against melanoma [74]. Here, MIA is linked to melanoma.